# Phase 2 Autoimmune Diseases trials recruiting: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 2 for Autoimmune Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Autoimmune Diseases trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/autoimmune-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 21, 2026 | NCT07779616 | Study of PTC844 in Participants With Active Rheumatoid Arthritis | PTC Therapeutics | Phase 2 | Recruiting | Rheumatoid Arthritis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779616) |
| July 28, 2026 | NCT07729826 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729826) |
| July 13, 2026 | NCT07699380 | METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) | University of Washington | Phase 2 | Recruiting | Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699380) |
| May 29, 2026 | NCT07614412 | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Ministry of Health, Saudi Arabia | Phase 2 | Not yet recruiting | Type 1 Diabetes Mellitus | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614412) |
| April 21, 2026 | NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 2 | Recruiting | IgA Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541287) |
| April 8, 2026 | NCT07517575 | Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis | R-Pharm International, LLC | Phase 2 | Recruiting | Juvenile Idiopathic Arthritis | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517575) |
| April 6, 2026 | NCT07513181 | Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely... | Athos Therapeutics Inc | Phase 2 | Recruiting | Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513181) |
| January 9, 2026 | NCT07328581 | A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis | iCell Gene Therapeutics | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328581) |
| August 5, 2025 | NCT07103746 | Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Autoimmune Disorders | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07103746) |
| May 21, 2025 | NCT06983028 | Atacicept in Multiple Glomerular Diseases | Vera Therapeutics, Inc. | Phase 2 | Recruiting | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983028) |
| February 11, 2025 | NCT06820281 | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Victor Chang Cardiac Research Institute | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820281) |
| February 10, 2025 | NCT06817889 | Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817889) |
| June 14, 2022 | NCT05418010 | Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis... | Queen Mary University of London | Phase 2 | Recruiting | Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05418010) |
| August 31, 2021 | NCT05027945 | A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Immunodeficiency, Hematopoietic Stem Cell Transplantation | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05027945) |
| December 10, 2020 | NCT04663204 | A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | University of Leicester | Phase 2 | Recruiting | Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04663204) |
| April 9, 2020 | NCT04339777 | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity | National Cancer Institute (NCI) | Phase 2 | Recruiting | Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04339777) |
| March 11, 2020 | NCT04304820 | Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Recruiting | Severe Aplastic Anemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04304820) |
| June 20, 2019 | NCT03993262 | Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis | Jena University Hospital | Phase 2 | Recruiting | Autoimmune Encephalitis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03993262) |
| September 17, 2018 | NCT03673748 | Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells | Red de Terapia Celular | Phase 2 | Recruiting | Lupus Nephritis, Lupus Erythematosus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03673748) |
| October 20, 2015 | NCT02579967 | Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies | National Cancer Institute (NCI) | Phase 2 | Recruiting | Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune... | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02579967) |
| September 16, 2009 | NCT00977977 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Recruiting | Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00977977) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 3 |
| AbelZeta Inc. | 1 |
| Fred Hutchinson Cancer Center | 1 |
| University of Washington | 1 |
| [PTC Therapeutics](https://specstream.ai/data/clinical-trials/company/ptc-therapeutics) | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Ministry of Health, Saudi Arabia | 1 |
| Jena University Hospital | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Queen Mary University of London | 1 |
| R-Pharm International, LLC | 1 |
| Victor Chang Cardiac Research Institute | 1 |
| Athos Therapeutics Inc | 1 |
| University of Leicester | 1 |
| Vera Therapeutics, Inc. | 1 |
| Jade Biosciences, Inc. | 1 |
| iCell Gene Therapeutics | 1 |
| Red de Terapia Celular | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| United Kingdom | 2 |
| Australia | 2 |
| Netherlands | 1 |
| Georgia | 1 |
| Mauritius | 1 |
| South Africa | 1 |
| Saudi Arabia | 1 |
| Germany | 1 |
| Russia | 1 |
| New Zealand | 1 |
| South Korea | 1 |
| Taiwan | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [Aircraft service companies in the United States](https://specstream.ai/data/businesses/aircraft-service-companies/united-states)
- [B2B radio and television commercials companies in the United States](https://specstream.ai/data/businesses/b2b-radio-and-television-commercials-companies/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
